Starfire Investment Advisers Inc. Acquires New Stake in Zimmer Biomet Holdings Inc (ZBH)

Starfire Investment Advisers Inc. acquired a new position in Zimmer Biomet Holdings Inc (NYSE:ZBH) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 3,799 shares of the medical equipment provider’s stock, valued at approximately $458,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Hexavest Inc. increased its stake in Zimmer Biomet by 3.0% in the fourth quarter. Hexavest Inc. now owns 317,253 shares of the medical equipment provider’s stock valued at $38,283,000 after acquiring an additional 9,108 shares during the last quarter. Daiwa SB Investments Ltd. increased its stake in Zimmer Biomet by 5.2% in the fourth quarter. Daiwa SB Investments Ltd. now owns 8,470 shares of the medical equipment provider’s stock valued at $1,022,000 after acquiring an additional 420 shares during the last quarter. Trust Co increased its stake in Zimmer Biomet by 56.2% in the third quarter. Trust Co now owns 2,678 shares of the medical equipment provider’s stock valued at $314,000 after acquiring an additional 964 shares during the last quarter. Chesley Taft & Associates LLC bought a new position in Zimmer Biomet in the fourth quarter valued at $202,000. Finally, Boltwood Capital Management bought a new position in Zimmer Biomet in the fourth quarter valued at $861,000. 86.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $121.68 on Wednesday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. The firm has a market cap of $24,721.96, a PE ratio of 38.26, a PEG ratio of 1.90 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 1-year low of $108.03 and a 1-year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter in the prior year, the company posted $1.79 earnings per share. The business’s revenue for the quarter was down .8% on a year-over-year basis. research analysts predict that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 29th. Shareholders of record on Friday, December 29th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 30.19%.

A number of research analysts recently commented on ZBH shares. Royal Bank of Canada reduced their target price on Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. SunTrust Banks set a $136.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Morgan Stanley reduced their price objective on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. BMO Capital Markets reduced their price objective on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Finally, Deutsche Bank raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research note on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $137.42.

TRADEMARK VIOLATION NOTICE: “Starfire Investment Advisers Inc. Acquires New Stake in Zimmer Biomet Holdings Inc (ZBH)” was published by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://weekherald.com/2018/01/17/starfire-investment-advisers-inc-acquires-new-stake-in-zimmer-biomet-holdings-inc-zbh.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply